Magnolia Neurosciences

Developing therapies for neurological diseases, including Alzheimer's, ALS and Parkinson’s.


As a member for the Accelerator Life Science partnership, the Partnership Fund invested in Magnolia as part of its initiative to grow life sciences. Magnolia’s technology was spun out from the MD Anderson Cancer Center in Texas and brought to New York.


Magnolia is a pre-clinical stage company developing the therapeutic potential for a lead dual leucine zipper kinase inhibitor (IACS-8287) in neurodegenerative diseases, such as Alzheimer’s disease, and amyotrophic lateral sclerosis and neuronal injuries.

Visit site